NAS
MLYS icon

Nykredit A/S’s Mineralys Therapeutics MLYS Stock Holding History

Nykredit A/S’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4K Buy
+535
New +$14.7K ﹤0.01% 1814

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Nykredit A/S's MLYS Position: Q2 2026 in Review

Nykredit A/S opened a new position in Mineralys Therapeutics (MLYS) in Q2 2026: 535 shares worth $14.4K. The stake represents ﹤0.01% of the portfolio and ranks #1814 among its holdings.

132 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Nykredit A/S held 535 shares of Mineralys Therapeutics worth $14.4K as of Q2 2026.
  • Mineralys Therapeutics was a new Nykredit A/S position in Q2 2026.
  • Mineralys Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1814 holding.
  • 132 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.